BIOMAT Database Logo BIOMAT Database Logo

4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation. 2015

Brahmam Medapi, and Priyanka Suryadevara, and Janupally Renuka, and Jonnalagadda Padma Sridevi, and Perumal Yogeeswari, and Dharmarajan Sriram
Department of Pharmacy, Birla Institute of Technology &Science Pilani Hyderabad Campus, Hyderabad 500078, India.

Mycobacterial DNA gyrase B subunit has been identified to be one of the potentially underexploited drug targets in the field of antitubercular drug discovery. In the present study, we employed structural optimization of the reported GyrB inhibitor resulting in synthesis of a series of 46 novel quinoline derivatives. The compounds were evaluated for their in vitro Mycobacterium smegmatis GyrB inhibitory ability and Mycobacterium tuberculosis DNA supercoiling inhibitory activity. The antitubercular activity of these compounds was tested over Mtb H37Rv strain and their safety profile was checked against mouse macrophage RAW 264.7 cell line. Among all, three compounds (23, 28, and 53) emerged to be active displaying IC₅₀ values below 1 μM against Msm GyrB and were found to be non-cytotoxic at 50 μM concentration. Compound 53 was identified to be potent GyrB inhibitor with 0.86 ± 0.16 μM and an MIC (minimum inhibitory concentration) of 3.3 μM. The binding affinity of this compound towards GyrB protein was analysed by differential scanning fluorimetry which resulted in a positive shift of 3.3 °C in melting temperature (Tm) when compared to the native protein thereby reacertaining the stabilization effect of the compound over protein.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000634 Aminoquinolines Quinolines substituted in any position by one or more amino groups.
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D059005 Topoisomerase II Inhibitors Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. DNA Gyrase Inhibitor,DNA Topoisomerase II Inhibitor,Topoisomerase 2 Inhibitors,Topoisomerase II Inhibitor,DNA Gyrase Inhibitors,DNA Topoisomerase II Inhibitors,DNA Type 2 Topoisomerase Inhibitors,Gyrase Inhibitor, DNA,Gyrase Inhibitors, DNA,II Inhibitor, Topoisomerase,Inhibitor, DNA Gyrase,Inhibitor, Topoisomerase II,Inhibitors, DNA Gyrase,Inhibitors, Topoisomerase 2,Inhibitors, Topoisomerase II
D027081 DNA Gyrase A bacterial DNA topoisomerase II that catalyzes ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. Gyrase binds to DNA as a heterotetramer consisting of two A and two B subunits. In the presence of ATP, gyrase is able to convert the relaxed circular DNA duplex into a superhelix. In the absence of ATP, supercoiled DNA is relaxed by DNA gyrase. DNA Gyrase A Subunit,DNA Gyrase B Subunit,DNA-Gyrase,GyrA Protein,GyrB Protein

Related Publications

Brahmam Medapi, and Priyanka Suryadevara, and Janupally Renuka, and Jonnalagadda Padma Sridevi, and Perumal Yogeeswari, and Dharmarajan Sriram
Design, synthesis and biological evaluation of 4-aminoquinoline derivatives as receptor-interacting protein kinase 2 (RIPK2) inhibitors.
December 2023, Journal of enzyme inhibition and medicinal chemistry,
Brahmam Medapi, and Priyanka Suryadevara, and Janupally Renuka, and Jonnalagadda Padma Sridevi, and Perumal Yogeeswari, and Dharmarajan Sriram
Synthesis and biological evaluation of novel 4-hydroxybenzaldehyde derivatives as tyrosinase inhibitors.
February 2010, European journal of medicinal chemistry,
Brahmam Medapi, and Priyanka Suryadevara, and Janupally Renuka, and Jonnalagadda Padma Sridevi, and Perumal Yogeeswari, and Dharmarajan Sriram
Design, synthesis and biological evaluation of 4-aminoquinoline-guanylthiourea derivatives as antimalarial agents.
October 2019, Bioorganic chemistry,
Brahmam Medapi, and Priyanka Suryadevara, and Janupally Renuka, and Jonnalagadda Padma Sridevi, and Perumal Yogeeswari, and Dharmarajan Sriram
Synthesis, biological evaluation and computational studies of pyrazole derivatives as Mycobacterium tuberculosis CYP121A1 inhibitors.
November 2022, RSC medicinal chemistry,
Brahmam Medapi, and Priyanka Suryadevara, and Janupally Renuka, and Jonnalagadda Padma Sridevi, and Perumal Yogeeswari, and Dharmarajan Sriram
Design, synthesis and biological evaluation of novel pyrimidinedione derivatives as DPP-4 inhibitors.
July 2018, Bioorganic & medicinal chemistry letters,
Brahmam Medapi, and Priyanka Suryadevara, and Janupally Renuka, and Jonnalagadda Padma Sridevi, and Perumal Yogeeswari, and Dharmarajan Sriram
Synthesis and biological evaluation of new enantiomerically pure azole derivatives as inhibitors of Mycobacterium tuberculosis.
April 2009, Bioorganic & medicinal chemistry letters,
Brahmam Medapi, and Priyanka Suryadevara, and Janupally Renuka, and Jonnalagadda Padma Sridevi, and Perumal Yogeeswari, and Dharmarajan Sriram
Design of novel quinoline-aminopiperidine derivatives as Mycobacterium tuberculosis (MTB) GyrB inhibitors: an in silico study.
July 2019, Journal of biomolecular structure & dynamics,
Brahmam Medapi, and Priyanka Suryadevara, and Janupally Renuka, and Jonnalagadda Padma Sridevi, and Perumal Yogeeswari, and Dharmarajan Sriram
Design, synthesis, and in vitro biological evaluation of novel benzimidazole tethered allylidenehydrazinylmethylthiazole derivatives as potent inhibitors of Mycobacterium tuberculosis.
January 2019, MedChemComm,
Brahmam Medapi, and Priyanka Suryadevara, and Janupally Renuka, and Jonnalagadda Padma Sridevi, and Perumal Yogeeswari, and Dharmarajan Sriram
Synthesis, molecular docking, and biological evaluation of novel 1,2,4-triazole-isatin derivatives as potential Mycobacterium tuberculosis shikimate kinase inhibitors.
August 2022, Chemical biology & drug design,
Brahmam Medapi, and Priyanka Suryadevara, and Janupally Renuka, and Jonnalagadda Padma Sridevi, and Perumal Yogeeswari, and Dharmarajan Sriram
Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
January 2013, European journal of medicinal chemistry,
Copied contents to your clipboard!